Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apixaban vs Enoxaparin for Postpartum VTE Prophylaxis
NCT07716332Not yet recruiting
- Sponsor
- PregnanTech
- Start
- Jul 2026
- Primary completion
- Apr 2027
01
Overview
Randomised, open-label trial of apixaban in venous thromboembolism (VTE) (2 arms), sponsored by PregnanTech. Primary endpoints: General Treatment Convenience Assessed by a Study-Specific Patient Satisfaction Questionnaire at 6 weeks, Medication Adherence Rate Assessed by Patient Self-Report at 6 weeks and 2 more. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
apixaban
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT07716332.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07716332.